Literature DB >> 34089000

Three different therapies to target PCSK9.

Andrew Robson1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34089000     DOI: 10.1038/s41569-021-00581-w

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels.

Authors:  Tanja Rothgangl; Melissa K Dennis; Paulo J C Lin; Rurika Oka; Dominik Witzigmann; Lukas Villiger; Weihong Qi; Martina Hruzova; Lucas Kissling; Daniela Lenggenhager; Costanza Borrelli; Sabina Egli; Nina Frey; Noëlle Bakker; John A Walker; Anastasia P Kadina; Denis V Victorov; Martin Pacesa; Susanne Kreutzer; Zacharias Kontarakis; Andreas Moor; Martin Jinek; Drew Weissman; Markus Stoffel; Ruben van Boxtel; Kevin Holden; Norbert Pardi; Beat Thöny; Johannes Häberle; Ying K Tam; Sean C Semple; Gerald Schwank
Journal:  Nat Biotechnol       Date:  2021-05-19       Impact factor: 54.908

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.